We found that reduced levels of AKR1B10 in the tumor tissues correlated significantly with advanced stages, greater invasiveness, increased tumor differentiation and poor survival of CRC patients, indicating that AKR1B10 is a potential tumor suppressor in CRC. Here, AKR1B10 is linked to neoplasm.